Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ice-CAP: A Phase I Trial of Ipatasertib in Combination With Atezolizumab in Patients With Advanced Solid Tumours With PI3K Pathway Hyperactivation

NCT03673787 is registered in ClinicalTrials.gov with Institute of Cancer Research, United Kingdom as lead sponsor.

NCT NCT03673787
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03673787 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ice-CAP: A Phase I Trial of Ipatasertib in Combination With Atezolizumab in Patients With Advanced Solid Tumours With PI3K Pathway Hyperactivation
Lead sponsor
Institute of Cancer Research, United Kingdom
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 13, 2018
Completion date
March 31, 2026
Enrollment
87 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme, prostate cancer metastatic, solid tumor